Graded claim

CBG for anxiety and stress

What does the evidence show for CBG and anxiety and stress?

In the only human trial of CBG's effects on anxiety and stress, a one-time 20 mg oral dose of CBG was associated with lower self-reported anxiety and stress in healthy adults, with no intoxication or measurable impairment. This is one small acute study — an early signal, not evidence of clinical efficacy. Other human CBG research exists but measures pharmacokinetics, not effects. Animal studies do not consistently reproduce an anxiety-reducing effect — one found no effect and another reported an anxiety-increasing effect — so the preclinical picture is mixed and does not confirm a benefit.

grade: LowEvidence divided: studies point both ways
What reaching the next rung would take

Any one of these, on top of what our registry already holds:

  • one larger, controlled, non-acute human trial
  • two independent human observational studies

The grade weighs the claim as a whole, across every study our registry holds on the question. How good any one of those papers is remains a separate matter, and you can judge each on its own terms.

Permalink

Studies that support the claim

2024

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial

Cuttler et al. · Scientific Reports · PMID 39003387 · study type: Human RCT

human RCT (double-blind, placebo-controlled crossover; n=34; 20 mg oral, acute) · human

PubMed →

Studies that point the other way

These results run against the claim. When small studies disagree, both sides stand until the evidence settles it.

2026

Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice

Mabou Tagne et al. · The Journal of Pharmacology and Experimental Therapeutics · PMID 41833244 · study type: Animal · preclinical

animal model (male mouse; pharmacokinetics + elevated plus maze) · animal

PubMed →
2022

The cannabis constituent cannabigerol does not disrupt fear memory processes or stress-induced anxiety in mice

Zhou et al. · Cannabis and Cannabinoid Research · PMID 34182770 · study type: Animal · preclinical

animal model (mouse PTSD / fear conditioning) · animal

PubMed →

One more study on this question is still in intake review. It joins the citations and the grade only if it clears its review.

Registered clinical trials on this question

What researchers have attempted is part of the answer, even where the attempt has produced no paper. Registration is not evidence, though, and none of these trials changes the grade above.

2026

Psychological and physiological effects of cannabigerol

Washington State University · N/A · n=100 · completed · no publication located

Healthy volunteers

NCT06638996 →
2023

Acute effects of cannabigerol on mood and cognition

Washington State University · Phase 1 · n=38 · completed · published

Anxiety, Stress, Cognition — Corresponds to Cuttler 2024 (PMID 39003387), which IS in our registry. Its NCT id returns no PubMed record.

NCT05257044 →

Source: ClinicalTrials.gov, retrieved 2026-08-31. A completed trial marked no publication located is one our search came up empty on, and searches by trial identifier are known to miss papers. So we write “never published” only when we have positive evidence for it.

Other conditions we cover

The CBG monograph covers the compound end to end, and the gap-map charts the questions nobody has tested yet.

CBG acts on α2-adrenoceptors, which help regulate blood pressure; anyone taking cardiovascular medication should consult a clinician before using CBG products. Nothing on this page is medical advice, and no statement here is a claim that CBG treats, cures, or prevents any condition. Grades are based on the studies we had checked as of 9 August 2026. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.